Pfizer says Covid-19 vaccine found to be "more than 90% effective"

Pfizer COVID-19 vaccine candidate over 90 percent effective, study shows

A vaccine jointly developed by Pfizer and BioNTech was 90 per cent effective in preventing Covid-19 infections in ongoing Phase 3 trials, the companies announced Monday. Here is all you need to know about the Covid-19 vaccine: * Pfizer and German partner BioNTech SE are the first drugmakers to show successful data from a large-scale clinical trial of a coronavirus vaccine.

The companies said they expect to supply up to 50 million vaccine doses globally in 2020, and up to 1.3 billion in 2021.

The UK has secured 40 million doses in total of the vaccine. Data showed that COVID-19 protection occurred 28 days after the initial vaccine through a two-dose inoculation schedule.

These findings are being called interim results, which means the numbers could change once the vaccine trial is complete. "We will continue to collect further data as the trial continues to enroll for a final analysis planned when a total of 164 confirmed COVID-19 cases have accrued". Ten of them were at the most advanced phase 3 stage, in which a vaccine's effectiveness is tested on a large scale, generally tens of thousands of people across several continents.> US President-elect Joe Biden Monday hailed as a cause for "hope" the news that a Covid-19 vaccine developed by Pfizer and BioNTech was 90 per cent effective - but warned of a long battle still ahead.

"It's important to note that we can not apply for FDA Emergency Use Authorization based on these efficacy results alone".


Peter Horby, professor of emerging infectious diseases and global health in the Nuffield Department of Medicine, University of Oxford, said Pfizer's announcement "feels to me like a watershed moment" in the pandemic.

Once the government agency has received and analysed two months' worth of trial safety data on at least half of the study's participants, the vaccine developers can apply for the authorisation. "This is better than most of us anticipated". He said: "Of all the current vaccines now in development the BioNtech product always looked like the most bang-per-buck as it is entirely focused on the part of the virus that binds to the human cell, the receptor binding domain".

The company says the vaccine candidate was found to be "more than 90% effective in preventing COVID-19" in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis.

"The results demonstrate that our mRNA-based vaccine can help prevent COVID-19 in the majority of people who receive it". "The data is not yet published or peer-reviewed, and the company news release could not be presented to outside experts under the terms of an embargo".

The global trial, which began in July, involved 43,538 participants, 42% of whom were said to come from "diverse backgrounds".

Related:

Comments

Latest news

US facing historic crises again, says Treasury Secretary-nominee Janet Yellen
Federal Reserve chairwoman Janet Yellen speaks at a press conference in Washington on December 13, 2017. The transition team said it was a historic first that all the positions will be filled by women.

Manufacturing activity loses pace in Nov, falls to three-month low: PMI
The Chinese National Bureau of Statistics will release the updated November Purchasing Management Index (PMI) figures today. The officials said the recovery trend has become stronger, but the pace remains uneven among sectors.

Royals to sign LHP Mike Minor
Jeff Passan of ESPN is now reporting that the deal of the multi-year variety, but the fiscal terms haven't been disclosed yet. In the 2015 offseason, he signed a two year deal in Kansas City despite knowing he'd miss all of 2016 due to shoulder issues.

Nokia to Construct Mobile Network on Moon
LTE is a proven commercial technology, has a large ecosystem of technology and component suppliers, and is deployed worldwide. Its objective will be "critical communication capabilities" for transmitting data, Nokia said.

Apple gets fined $12 million in Italy for its water resistance claims
It is said that Apple failed to fix iPhones under warranty that had been damaged by water. It will be interesting to see if competition watchdogs in other countries follow suit.

Other news